Introduction
Nowadays there is still a large demand for synthetic bone replacement for regeneration, and repair of critical size bone defects. These defects often result from accidents, tumours, trauma or disease. In many cases the defects cannot be repaired by the body alone. In this context, the method of 3D printing allows to produce scaffolds to mimic bone structures [1] with a high porosity between 50 − 90 % [2] . These days calciumphosphates are approved as promising materials for bone replacement [3] . Scaffolds can be generated from tricalciumphosphate (TCP) or hydroxyapatite (HA) and both materials offer different degrees of osteoclastic resorption and solubility [4] . The aim of this study is to provide the 3D printed scaffolds with a local drug delivery (LDD) function in order to support bone regeneration. Therefore, 3D printed tricalciumphosphate scaffolds are infiltrated with biodegradable polymers and biomolecules.
Methods
3D printing technology. With 3D printing it is possible to generate physical models out of 3D computer data. The used tricalciumphosphate granulate is supplied by BioCer Entwicklungs-GmbH (Bayreuth, Germany). Figure 1 shows the steps of the 3D printing process for the manufacturing of TCP scaffolds. Therefore a 3D medical image dataset is sliced into a stack of 2D bitmaps, which are afterwards printed on a TCP powderbed by a layer by layer process as described in the following:
Step (1) A recoater blade deposits a thin layer of ceramic powder on the building platform.
Step (2) Liquid adhesive binder is printed on selected areas on this powderbed and the ceramic powder is bonded in the selected wetted regions.
Step (3) and (4) The building platform is lowered according to a defined layer thickness and a new layer of TCP powder is deposited on the first layer. Now the process restarts by printing the next layers to produce the 3D part successively layer by layer. Upon completion of the last layer, the generated model is freed from unbound powder (Step (5)). The resulting body obtains its desired mechanical properties by sintering at 1275°C. Details of the process have been published previously [5] . In this study, TCP cylinders with 10 mm in diameter, 11 mm in height containing horizontal and vertical cavities with of 500 ± 50 µm in diameter were fabricated ( Figure 2 ). Infiltration with biodegradable polymers and biomolecules. The copolymer poly(D,L-lactide-co-glycolide) (50/50, Resomer RG 503H, Boehringer Ingelheim, Germany) with an approximate degradation time of 3 months and fluorescein isothiocyanate-labelled bovine serum albumin (BSA-FITC, Sigma, Germany) were used as model biodegradable polymer and biomolecule respectively. For infiltration, RG 503H has been dissolved in chloroform (Roth GmbH, Germany) at 5 w%. and poured over fabricated TCP cylinders inserted into a glass tube. After 30 minutes of infiltration with intermediate invertion of the glass tube every 5 minutes, TCP scaffolds were removed and placed on a paper towel. After 24 hours of drying in the air, all samples were dried again for 36 hours at 35 degrees in vacuum to ensure complete removal of chloroform. Subsequently, the infiltration process was repeated with BSA-FITC (0.5 mg/ml in distillated water) and RG 503H until a (RG 503H/BSA-FITC) 2 /RG 503H coating was obtained. Coating morphology was assessed via the electron micro-scope Philips XL 30 ESEM (Philips Electron Optics, Eindhoven, The Netherlands) operating in the ESEM mode.
In vitro drug release study. The time course of BSA-FITCrelease from infiltrated TCP scaffolds was determined at 37 °C in 10 mM Tris buffer pH 7.0. Individual samples were immersed in 4 mL elution medium for a total duration of at least 520 h. The elution medium was renewed at periodic intervals in order to ensure the maintenance of sink conditions. The released concentration of BSA-FITC was measured by means of the plate reader FLUOstar Optima (BMG Labtech, Offenburg, Germany). 
Results and Discussion

Conclusion
The 3D printing process based on TCP powder is a promising method for the production of bone-reconstructing scaffolds. Within this study, we showed successful infiltration of fabricated scaffolds with a biodegradable polymers and a model biomolecule. An initial drug release study evidenced a sustained drug release. In future, the infiltration of the 3D-printed scaffolds with different growth factors with independently tunable drug release profiles is conceivable.
